Surveillance of adverse events following immunization: 10 years' experience in Oman;Surveillance des manifestations postvaccinales indésirables: Dix ans d'expérience à Oman

Eastern Mediterranean Health Journal

Volumn 16, Issue 5, 2010, Pages 474-480

  Awaidy, S Al ^a   Bawikar, S ^a   Prakash, K P ^a   Alrawahi, B ^a   Mohammed, A J ^a  

^a MINISTRY OF HEALTH   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; TETANUS TOXOID;

ADVERSE OUTCOME; ANAPHYLAXIS; ARTICLE; BCG VACCINATION; CHILD; CONVULSION; DESCRIPTIVE RESEARCH; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFLUENZA VACCINATION; MALE; MASS IMMUNIZATION; OMAN; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; TETANUS PROPHYLAXIS; UNSTEADINESS;

EID: 77953785736     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2010.16.5.474     Document Type: Article

References (22)

1. Global status of immunization safety: a report based on the WHO/UNICEF Joint Reporting Form. Weekly epidemiology record, 2003, 78(7):44-7.
2. Mansoor O et al. Immunization safety surveillance: Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila, World Health Organization Regional Office for the Western Pacific, 1999.
3. Surveillance of adverse events following immunization, field guide for managers of immunization programmes. Geneva, World Health Organization, 1997.
4. The milestones of EPI in Oman. Manual on expanded program on immunization, 3rd ed. Muscat, Oman, Ministry of Health, 2003:1-62.
5. Ministry of Health, Oman. Hypersensitivity reactions reported with MR vaccine. Community health and disease surveillance newsletter, 1995, 4(3):7-8.
6. Ministry of Health, Oman. An unusual presentation of AEFI. Community health and disease surveillance newsletter, 2000, 9(1):10.
7. Centers for Disease Control and Prevention (CDC). Surveillance for Safety after Immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Morbidity and mortality weekly report, 2003, 52(1):1-24.
8. Lawrence G et al. Surveillance of adverse events following immunization in Australia 2004. Communicable diseases intelligence, 2005, 29(3):248-62.
9. Supplementary information on vaccine safety, Part2: Background rates of adverse events following immunization. Geneva, World Health Organization, 2000.
10. Stratton KR, Howe CJ, Johnston RB. Research strategies for assessing adverse events associated with vaccines: a workshop summary. Washington DC, National Academy Press, 1994.
11. National Report (interim) on Immunization Vaccine Safety Issues and Surveillance 1998. Reported adverse events temporarily associated with vaccine administration in Canada: 1993 to 1997 summary tables. Journal of the Canadian Pediatric Society, 1998, 4 (Suppl C).
12. Szczuka I. [Adverse event after BCG vaccination in Poland in the years 1994-1997]. Pneumonologia i alergologia polska, 1999, 67(5-6):208-16 [in Polish].
13. Praveen KN et al. Outbreak of Bacillus Calmette-Guerin associated lymphadenitis and abscesses in Jamaican children. Pediatric infectious disease journal, 1990, 9(12):890-3.
14. Prakash MJ et al. Safety of the intra-dermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bulletin of World Health Organization, 2001, 79(4):337-43.
15. Romanus V et al. Adverse reactions in healthy and immuno compromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden. Acta paediatrica, 1993, 82(12):1043-52.
16. Dodoo AN et al. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana. Drug safety, 2007, 30(4):347-56.
17. D'Souza RM et al Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Communicable diseases intelligence, 2000, 24(2):27-33.
18. Canadian national report on immunization. Canada communicable disease report, 2006, 32(Suppl. 3):1-44.
19. Lawrence G et al. Adverse events following immunisation: Australia 2000-2002. Communicable diseases intelligence, 2003, 27:307-23.
20. Lawrence G et al. Surveillance of adverse events following immunisation: Australia 2002-2003. Communicable diseases intelligence, 2004, 28:324-38.
21. Lawrence G et al. Surveillance of adverse events following immunization in Australia 2004. Communicable diseases intelligence, 2005, 29:248-62.
22. Lawrence G et al. Surveillance of adverse events following immunisation: Australia 2005. Communicable diseases intelligence, 2006, 30:319-33.